Shares of Accentia Biopharmaceuticals soared 54 percent Thursday after the drug developer announced positive results from a small clinical trial of its BiovaxId cancer therapy for relapsed Follicular Non-Hodgkins Lymphoma. In the trial, 20 patients, or 80 percent, who took BiovaxId following chemotherapy saw their cancer go into remission for 20 to 51 months. The drug relied on the patient's cells to create a therapy that is designed to get the immune system to recognize the cancer and attack it.
- here's the AP report on Accentia
In May the FDA granted fast track status to Accentia's drug. Report